

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (withdrawn) Isolated nucleic acid molecules, comprising a heavy chain and a light chain nucleic acid sequence that encodes a heavy chain and a light chain amino acid sequence, wherein said heavy chain and light chain amino acid sequences comprise a monoclonal rabies virus neutralizing antibody that specifically binds to a rabies virus protein.

2. (withdrawn) The isolated nucleic acid molecules of claim 1, comprising a cDNA sequence of a heavy chain (SEQ. ID. NO.: 1) and a cDNA sequence of a light chain (SEQ. ID. NO: 2).

3. (canceled)

4. (canceled)

5. (withdrawn) A fused gene encoding a chimeric immunoglobulin light chain, comprising:

- a) a first DNA sequence encoding an immunoglobulin light chain variable region of a monoclonal rabies virus neutralizing antibody produced by a heterhybridoma cell line; and
- b) a second DNA sequence encoding a human light chain constant region.

6. (withdrawn) An expression vector, comprising a fused gene of claim 5.

7. (withdrawn) A host cell, comprising an expression vector of claim 6.

8. (withdrawn) A fused gene encoding a chimeric immunoglobulin heavy chain, comprising:

- a) a first DNA sequence encoding an immunoglobulin heavy chain variable region of a monoclonal rabies virus neutralizing antibody produced by a heterhybridoma cell line; and
- b) a second DNA sequence encoding a human heavy chain constant region.

9. (withdrawn) An expression vector, comprising an expression vector of claim 8.

10. (withdrawn) A host cell, comprising an expression vector of claim 9.

11. (withdrawn) An isolated monoclonal rabies virus neutralizing antibody, comprising a fused gene encoding a chimeric immunoglobulin product of a claim 6 and a fused gene encoding a chimeric immunoglobulin product of claim 9.

12. (withdrawn) A method of treating an individual exposed to a rabies virus, comprising:

- a) administering to said individual a therapeutically effective amount of a human monoclonal rabies virus neutralizing antibody of claim 3; and
- b) preventing a spread of said rabies virus to a central nervous system.

13. (new) An antibody comprising a heavy chain polypeptide comprising an amino acid sequence having at least 80% amino acid sequence homology to SEQ ID NO:3 and a light chain polypeptide comprising an amino acid sequence having at least 80% amino acid sequence homology to SEQ ID NO:4.

14. (new) The antibody according to claim 13, wherein said antibody has rabies virus neutralizing activity.

15. (new) The antibody according to claim 14 comprising a heavy chain polypeptide comprising an amino acid sequence having at least 90% amino acid sequence homology to SEQ

Reply to Office Action dated September 9, 2003

ID NO:3 and a light chain polypeptide comprising an amino acid sequence having at least 90% amino acid sequence homology to SEQ ID NO:4.

16. (new) An antibody comprising a heavy chain polypeptide having the amino acid sequence SEQ ID NO:3 and a light chain polypeptide having the amino acid sequence SEQ ID NO:4.

17. (new) The antibody comprising a fragment of the antibody according to claim 16, said fragment selected from the group consisting of Fv fragments, Fab fragments, and F(ab')<sub>2</sub> fragments.

18. (new) The antibody according to claim 17, wherein the antibody is an IgG1 antibody.